The global liver disease treatment market size is predicted to grow USD 22.46 billion by 2026 from USD 12.9 billion in 2021, growing at a CAGR of 11.72% during the forecast period.
The liver is a vital organ of the body performing umpteen complex functions such as fighting infections, removing toxins, bile secretion, and it produces clotting factors, proteins, and cholesterol, among others. Malfunctioning of the liver can be life-threatening. It can cause multiple acute and chronic diseases (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumor, and liver cirrhosis). The initial liver damage symptoms include nausea, fatigue, diarrhea, jaundice, swollen abdomen, and mental disorientation. Acute liver damage can be treated through proper medication if detected early. Otherwise, a liver transplant is required. Liver damage can be prevented by adopting a healthy lifestyle and practicing proper hygiene.
The growth of the global liver disease treatment market is majorly driven by factors such as a boost in Research & Development investment, an unorganized lifestyle, rising public awareness, growth in the geriatric population, and unmet needs for liver treatment cancer. Additionally, spur in demand for alcohol has increased the risk of liver cirrhosis. According to the World Health Organization, alcohol consumption is anticipated to cause 20% to 50% liver cirrhosis. Furthermore, the growing obese population has also increased the risk of non-alcoholic fatty liver disease caused by the build-up of fat in the liver. The obese population has doubled since 1980. In 2014, approximately 13% of the world’s population, more than 600 million adults, were obese as per the World Health Organization.
The key restraints of the market are complex drug approval procedures, side-effects of the product (fatigue, fever, and depression), high cost incurred for the product’s R&D process, and competition from alternative medicine (Herbal, Natural medicine).
Impact of COVID-19 on the global liver disease treatment market:
The COVID-19 disease is an illness caused by the SARS-CoV-2 virus. The pandemic has been declared a healthcare emergency issue by the World Health Organization (WHO). The pandemic crisis has negatively impacted the patients with liver disease who have not contracted COVID-19. Senior people and patients of any age with severe medical conditions like liver disease are at high risk from COVID-19. The mortality and severity of COVID-19 patients are significantly associated with liver dysfunction. Liver damage in patients with COVID-19 may be due to several factors like the action of the virus or the immune system or liver cells and the toxicity of the drugs used during the treatment. Therefore, the liver disease treatment market shares are to have significant growth opportunities in the coming years.
Market Size Available
2020 to 2026
2021 to 2026
By Treatment Modality, Disease Type, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
This research report on the global liver disease treatment market has been segmented and sub-segmented based on the treatment modality, disease type, and region.
Liver Disease Treatment Market - By Treatment Modality:
Based on the treatment modality, the antiviral treatment modality segment accounted for the largest share in the market in 2019. The rising population with increasing alcohol usage and expanding liver disease frequency augment the liver disease treatment market. In addition, the segment witnessed a profitable market growth rate due to the presence of powerful pipeline drugs.
Liver Disease Treatment Market - By Disease Type:
Based on the disease type, the liver cancer segment is ruling with the dominant shares of the market due to increasing incidences of cancer and rising awareness over the availability of different treatment procedures.
Liver Disease Treatment Market - By Region:
Geographically, the North American market is forecasted to dominate the global liver disease treatment market during the forecast period. The growth of this regional market is majorly driven by the rising liver diseases such as hepatitis and escalating healthcare expenditure. In addition, the increasing patient population with liver diseases and new product launches targeting the unique medical needs of growing awareness surges the market demand. The U.S secures the highest market share in liver disease treatment during the assessment period. The number of adults diagnosed with liver disease in the U.S is 4.5 million, and the mortality rate is 44,358. The presence of many older adults and the easy availability of liver disease treatments escalate the market growth. As per the estimation, 1 in 10 Canadians or more than 3million have liver disease.
The European liver disease treatment market stands in the second position. It is said to have a good and robust growth rate during the review period. Liver disease in Europe is a critical issue with growing cases of Cirrhosis and liver. An estimated 5million carriers with hepatitis C in Western Europe. According to the WHO, liver cancer is responsible for approximately 47,000 deaths every year in the EU. The massive intake of alcohol, unhealthy diet, and genetic disorders make up the market growth. The Germany, UK, and France account for the region's highest share in liver disease treatment. Germany is leading the market with factors like increasing reimbursement policies for liver diseases, the government, and other organizations bringing awareness to the public by conducting liver disease programs.
The Asia-Pacific is expected to have rapid growth in the liver disease treatment market to grow at the earliest. The presence of new healthcare infrastructure needs, mounting hepatitis, and hepatocellular carcinoma flourish the market demand. Japan and Australia are encouraging market growth due to acceptable government initiatives related to drug cost adjustment and new drugs for liver disease treatments. The above-mentioned factors spur the region's market growth. Every year in India, around 10 lakh patients are newly diagnosed with liver cirrhosis. The surge in the obese and diabetic population double the market growth in India.
Latin America is the second region, followed by Asia-Pacific, to have prominent market growth in liver disease treatment during the assessment period. The increasing elderly population and the growing occurrence of liver diseases are driving the market growth successfully. Brazil is to lead the market shares in the region. Advanced Biological Laboratories agreed with the LALREAN (Latin America Liver Research Awareness and Educational Network) to study liver diseases representing an active cohort of over 7,000HCV infected patients comprising 18 treatment centers. The Brazilian market growth is due to the frequent change of obesity-related metabolic syndrome results in a high frequency of non-alcoholic fatty liver disease.
The Middle East & Africa have had significant growth in the liver disease treatment market throughout the estimated period. The rising patient population suffering from liver cirrhosis is escalating the market demand. The fueling public awareness and high-level government commitments are lavishing the market growth in the region. The MEA is projected to have significant growth opportunities because of rapidly developing healthcare amenities among Saudi Arabia, Oman, and Qatar. Over 200,000 deaths took place in Sub-Saharan Africa due to liver diseases resulting in liver cirrhosis and hepatocellular carcinoma. More than 80% of Africa's liver disease burden is due to endemic blood-borne virus infections like HIV, hepatitis B, and hepatitis C.
NOTABLE COMPANIES IN THE MARKET:
Key participants dominating the Global Liver Disease Treatment Market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Treatment Modality
5.1.5 Immunosuppressive Agents
5.1.8 Y-o-Y Growth Analysis, By Product
5.1.9 Market Attractiveness Analysis, By Product
5.1.10 Market Share Analysis, By Product
5.2 Disease Type
5.2.3 Non-Alcoholic Fatty Liver Disease
5.2.4 Alcohol Induced
5.2.5 Liver Cancer
5.2.7 Y-o-Y Growth Analysis, By Type
5.2.8 Market Attractiveness Analysis, By Type
5.2.9 Market Share Analysis, By Type
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Product
22.214.171.124 By Type
126.96.36.199 By Application
188.8.131.52 By Indication
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By Type
22.214.171.124 By Application
126.96.36.199 By Indication
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By Type
18.104.22.168 By Application
22.214.171.124 By Indication
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Gilead Science Inc
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer Inc.
8.3 Merck & Co.
8.4 Johnson & Johnson
8.8 Abbott Laboratories
8.9 Bayer Schering AG
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities